Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
CVS Health (NYSE: CVS) announced Friday that it has reduced employee bonuses due to lower-than-expected profits in 2024. The healthcare giant faced mounting costs, particularly from its Medicare plans, impacting overall financial performance.
A company spokesperson stated, “We did not meet our financial goals in 2024, and that’s reflected in our corporate bonus.”
CVS experienced a surge in Medicare enrollments, leading to increased expenses. The company also struggled with higher medical service utilization, a shift in quality ratings, and elevated costs from sicker Medicaid members. These factors contributed to financial setbacks, prompting executive changes and restructuring efforts.
In October, CVS replaced CEO Karen Lynch with longtime company executive David Joyner following investor pressure, including from activist Glenview Capital. Joyner has since initiated cost-cutting measures and appointed a new insurance head to stabilize operations.
Despite financial challenges, CVS recently exceeded Wall Street’s fourth-quarter profit expectations and provided an annual forecast aligning with analyst estimates. This signals potential improvement under the new leadership.
As CVS navigates economic headwinds, its strategic adjustments will be crucial in restoring growth and shareholder confidence.
